Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global, Multicenter, Three Arms, Open-label Randomized Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension Compared to Taxotere® (Docetaxel Injection Concentrate) in Triple-negative Breast Cancer Patients With Locally Advanced or Metastatic Breast Cancer After Failure to Prior Chemotherapy

NCT03671044 is registered in ClinicalTrials.gov with Jina Pharmaceuticals Inc. as lead sponsor.

NCT NCT03671044
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03671044 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global, Multicenter, Three Arms, Open-label Randomized Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension Compared to Taxotere® (Docetaxel Injection Concentrate) in Triple-negative Breast Cancer Patients With Locally Advanced or Metastatic Breast Cancer After Failure to Prior Chemotherapy
Lead sponsor
Jina Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
July 10, 2018
Completion date
December 31, 2025
Enrollment
657 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer